Amgen Inc. (AMGN) To Go Ex-Dividend on November 21st

Amgen Inc. (NASDAQ:AMGN) announced a quarterly dividend on Friday, October 31st. Shareholders of record on Friday, November 21st will be paid a dividend of 2.38 per share by the medical research company on Friday, December 12th. This represents a c) dividend on an annualized basis and a yield of 2.8%. The ex-dividend date is Friday, November 21st.

Amgen has increased its dividend payment by an average of 0.1%per year over the last three years and has increased its dividend every year for the last 14 years. Amgen has a dividend payout ratio of 44.2% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Amgen to earn $21.39 per share next year, which means the company should continue to be able to cover its $9.52 annual dividend with an expected future payout ratio of 44.5%.

Amgen Stock Up 0.1%

Shares of NASDAQ:AMGN traded up $0.17 on Wednesday, reaching $344.16. The company had a trading volume of 222,147 shares, compared to its average volume of 2,735,767. The firm’s 50 day simple moving average is $297.43 and its 200-day simple moving average is $291.24. Amgen has a 52-week low of $253.30 and a 52-week high of $345.84. The company has a current ratio of 1.31, a quick ratio of 0.98 and a debt-to-equity ratio of 7.24. The firm has a market capitalization of $185.32 billion, a PE ratio of 28.08, a PEG ratio of 2.61 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, November 4th. The medical research company reported $5.64 EPS for the quarter, beating analysts’ consensus estimates of $5.01 by $0.63. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The company had revenue of $9.56 billion during the quarter, compared to analysts’ expectations of $8.98 billion. During the same period last year, the business posted $5.58 earnings per share. The firm’s revenue was up 12.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. As a group, analysts expect that Amgen will post 20.62 earnings per share for the current fiscal year.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.